In a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial based on patients with pSS, the administration of telitacicept at a dose of 160 mg significantly reduced patient ESSDAI scores, the Multidimensional Fatigue Inventory (MFI)-20, and serum immunoglobulin IgG, IgA, and IgM levels, as compared to levels in those with the placebo (p < 0.05) (8). The gene discussed is CD40LG; the disease is peeling skin syndrome.